Vaccine trials for the clinician: Prospects for tumor antigens

Oncologist

Volumn 2, Issue 5, 1997, Pages 284-299

  Osanto, Susanne ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antigen presenting cells; Cytotoxic T cell lymphocytes; Gene therapy; Genetic engineering; Histocompatibility antigens class I; Peptides; T lymphocyte epitopes; Tumor antigens; Vaccination; Vaccines

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA VACCINE; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNIZATION; CANCER REGRESSION; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG POTENCY; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; MELANOMA; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION;

EID: 0030721972     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.2-5-284     Document Type: Article

References (11)

1. Cassel WA, Murray DR, Philips HS. A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle Disease virus oncolysate. Cancer 1983;52:856-860.
2. Hoover HC Jr, Surdyke M, Dangel R et al. Delayed hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: bacillus Calmette-Guérin vaccine. Cancer Res 1984;44:1671-1676.
3. Hoover HC, Surdyke M, Dangel RB et al. Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer 1985;55:1236-1243.
4. Hollinshead A, Stewart THM, Takita H et al. Adjuvant specific active lung cancer immunotherapy trials. Cancer 1987;60:1249-1262.
5. Morton DL. Active immunotherapy against cancer. Present status. Semin Oncol 1986;13:180-185.
6. Mitchell MS, Harel W, Kempf RA et al. Active-specific immunotherapy for melanoma. J Clin Oncol 1990;8:856-869.
7. Berd D, Maguire HC, McCue P et al. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunological results in 64 patients. J Clin Oncol 1990;8:1858-1867.
8. McCune CS, O'Donnell RW, Marquis DM et al. Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol Immunother 1990;32:62-66.
9. Bystryn JC, Oratz R, Roses D et al. Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage-II malignant melanoma. Cancer 1992;69:1157-1164.
10. Morton D, Foshag L, Hoon D et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;216:463-482.
11. Patel BT, Lutz MB, Schlag P et al. An analysis of autologous T-cell antitumor response in colon carcinoma patients following active specific immunization (ASI). Int J Cancer 1992;51:878-885.